Technetium (99mTc) exametazime is a radiopharmaceutical sold under the trade name Ceretec, and is used by nuclear medicine physicians for the detection of altered regional cerebral perfusion in stroke[1] and other cerebrovascular diseases.

It can also be used for the labelling of leukocytes to localise intra-abdominal infections[2] and inflammatory bowel disease.

[3] Exametazime (the part without technetium) is sometimes referred to as hexamethylpropylene amine oxime or HMPAO, although correct chemical names are:[4] The drug consists of exametazime as a chelating agent for the radioisotope technetium-99m.

Both enantiomeric forms of exametazime are used—the drug is racemic.

[5] The third stereoisomer of this structure, the meso form, is not included.